Skip to main content

Table 3 Premenopausal androgens and SHBG and breast cancer risk: Nurses' Health Study II, 1999 to 2009

From: Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses' Health Study II

 

1st Quintile

2nd Quintile

3rd Quintile

4th Quintile

5th Quintile

 
 

OR (95% CI)

OR (95% CI)

OR (95% CI)

OR (95% CI)

OR (95% CI)

P trend

Testosterone

      

   Cutpoints, ng/dL

< 19

≥ 19 to 22.9

≥ 23 to 27.9

≥ 28 to 34.9

≥ 35

 

   No. cases/No. controls*

126/259

122/244

107/246

118/240

150/256

 

   All cancers

1.0 (referent)

1.0 (0.7 to 1.4)

0.9 (0.6 to 1.2)

0.9 (0.7 to 1.3)

1.2 (0.9 to 1.7)

0.32

   Invasive

1.0 (referent)

1.2 (0.8 to 1.7)

1.0 (0.7 to 1.4)

0.9 (0.6 to 1.3)

1.4 (1.0 to 2.0)

0.23

   ER+/PR+

1.0 (referent)

1.5 (1.0 to 2.3)

1.1 (0.7 to 1.8)

1.0 (0.6 to 1.5)

1.7 (1.1 to 2.6)

0.10

   In situ

1.0 (referent)

0.9 (0.5 to 1.5)

0.9 (0.5 to 1.5)

1.2 (0.7 to 1.9)

1.0 (0.6 to 1.7)

0.64

Free testosterone

      

   Cutpoints, ng/dL

< 0.14

≥ 0.14 to 0.179

≥ 0.18 to 0.239

≥ 0.24 to 0.309

≥ 0.31

 

   No. cases/No. controls

130/248

108/246

137/249

100/246

142/248

 

   All cancers

1.0 (referent)

0.8 (0.6 to 1.1)

1.0 (0.7 to 1.4)

0.8 (0.6 to 1.1)

1.1 (0.8 to 1.5)

0.61

   Invasive

1.0 (referent)

0.9 (0.6 to 1.3)

1.1 (0.8 to 1.6)

0.9 (0.6 to 1.3)

1.1 (0.8 to 1.6)

0.49

   ER+/PR+

1.0 (referent)

1.0 (0.6 to 1.5)

1.1 (0.7 to 1.7)

1.0 (0.6 to 1.5)

1.5 (1.0 to 2.2)

0.09

   In situ

1.0 (referent)

0.9 (0.6 to 1.6)

1.1 (0.7 to 1.8)

0.7 (0.4 to 1.3)

1.3 (0.8 to 2.1)

0.47

DHEAS

      

   Cutpoints, μg/dL

< 55

≥ 55 to 76.9

≥ 77 to 100.9

≥ 101 to 135.9

≥ 136

 

   No. cases/No. controls

123/249

96/253

136/250

146/251

127/251

 

   All cancers

1.0 (referent)

0.8 (0.5 to 1.1)

1.1 (0.8 to 1.6)

1.2 (0.9 to 1.6)

1.0 (0.7 to 1.4)

0.30

   Invasive

1.0 (referent)

0.8 (0.5 to 1.1)

1.1 (0.8 to 1.6)

1.1 (0.8 to 1.6)

1.1 (0.7 to 1.5)

0.29

   ER+/PR+

1.0 (referent)

0.9 (0.5 to 1.4)

1.4 (0.9 to 2.2)

1.5 (1.0 to 2.2)

1.3 (0.8 to 2.0)

0.05

   In situ

1.0 (referent)

0.8 (0.5 to 1.4)

1.0 (0.6 to 1.7)

1.3 (0.8 to 2.2)

0.9 (0.5 to 1.6)

0.62

SHBG

      

   Cutpoints, nmol/mL

< 40

≥ 40 to 54.9

≥ 55 to 70.9

≥ 71 to 91.9

≥ 92

 

   No. cases/No. controls

110/253

117/245

131/249

136/249

130/250

 

   All cancers

1.0 (referent)

1.1 (0.8 to 1.5)

1.2 (0.8 to 1.6)

1.2 (0.9 to 1.7)

1.2 (0.8 to 1.6)

0.23

   Invasive

1.0 (referent)

1.2 (0.8 to 1.8)

1.4 (1.0 to 2.0)

1.3 (0.9 to 1.9)

1.3 (0.9 to 1.9)

0.13

   ER+/PR+

1.0 (referent)

1.1 (0.7 to 1.7)

1.3 (0.8 to 2.0)

1.3 (0.9 to 2.0)

1.2 (0.8 to 1.8)

0.35

   In situ

1.0 (referent)

0.8 (0.5 to 1.4)

0.9 (0.5 to 1.5)

1.0 (0.6 to 1.7)

0.8 (0.5 to 1.4)

0.72

  1. All cancers: Conditional logistic regression for all cancers controlling for age at menarche, parity/age at first birth, BMI at age 18, family history of breast cancer, history of benign breast disease. Invasive, ER+/PR+, in situ tumors: Unconditional logistic regression for invasive, ER+/PR+, and in situ disease controlling for factors listed above and matching factors. *No. cases/No. controls are for all cancers; Overall No. cases/No. controls for invasive and ER+/PR+ cancers are in Table 4.